New hope for newborn seizures: levetiracetam tested as safer alternative
NCT ID NCT07401433
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed trial tested whether levetiracetam works better and safer than the standard drug phenobarbitone for stopping seizures in newborns. 260 babies with seizures received either levetiracetam or phenobarbitone. Researchers measured how quickly seizures stopped and if they returned. The goal is to find a treatment that controls seizures faster with fewer side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- levetiracetam
- What this could lead to
- If successful, levetiracetam could become a safer, more effective first-line treatment for neonatal seizures, reducing brain injury risk.
- What could go wrong
- This is a single-center completed trial; results may not apply broadly. Levetiracetam may not outperform phenobarbitone in all settings, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEONATAL SEIZURES are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gomal Medical College
Dera Ismāīl Khān, KPK, 29111, Pakistan
More trials for these conditions
Other studies related to the condition(s) this trial covers.